| Mutations associated with acquired resistance to PD-1 blockade in melanoma JM Zaretsky, A Garcia-Diaz, DS Shin, H Escuin-Ordinas, W Hugo, ... New England Journal of Medicine 375 (9), 819-829, 2016 | 3058 | 2016 |
| Regulation and function of the PD-L1 checkpoint C Sun, R Mezzadra, TN Schumacher Immunity 48 (3), 434-452, 2018 | 1871 | 2018 |
| Identification of CMTM6 and CMTM4 as PD-L1 protein regulators R Mezzadra, C Sun, LT Jae, R Gomez-Eerland, E De Vries, W Wu, ... Nature 549 (7670), 106-110, 2017 | 610 | 2017 |
| Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers W Scheper, S Kelderman, LF Fanchi, C Linnemann, G Bendle, ... Nature medicine 25 (1), 89-94, 2019 | 525 | 2019 |
| Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer M Ruscetti, JP Morris, R Mezzadra, J Russell, J Leibold, PB Romesser, ... Cell 181 (2), 424-441. e21, 2020 | 281 | 2020 |
| Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts A Moiani, Y Paleari, D Sartori, R Mezzadra, A Miccio, C Cattoglio, ... The Journal of clinical investigation 122 (5), 1653-1666, 2012 | 212 | 2012 |
| Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold DW Vredevoogd, T Kuilman, MA Ligtenberg, J Boshuizen, KE Stecker, ... Cell 178 (3), 585-599. e15, 2019 | 196 | 2019 |
| Correction of β‐thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients EA Roselli, R Mezzadra, MC Frittoli, G Maruggi, E Biral, F Mavilio, ... EMBO molecular medicine 2 (8), 315-328, 2010 | 121 | 2010 |
| Senescence rewires microenvironment sensing to facilitate antitumor immunity HA Chen, YJ Ho, R Mezzadra, JM Adrover, R Smolkin, C Zhu, K Woess, ... Cancer discovery 13 (2), 432-453, 2023 | 91 | 2023 |
| TCR repertoires of intratumoral T‐cell subsets C Linnemann, R Mezzadra, TNM Schumacher Immunological reviews 257 (1), 72-82, 2014 | 78 | 2014 |
| Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer R Yaeger, R Mezzadra, J Sinopoli, Y Bian, M Marasco, E Kaplun, Y Gao, ... Cancer discovery 13 (1), 41-55, 2023 | 48 | 2023 |
| SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing R Mezzadra, M de Bruijn, LT Jae, R Gomez-Eerland, A Duursma, ... PLoS One 14 (2), e0212053, 2019 | 39 | 2019 |
| Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade A Ghosh, J Michels, R Mezzadra, D Venkatesh, L Dong, R Gomez, ... The Journal of Clinical Investigation 132 (18), 2022 | 12 | 2022 |
| CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1 B Miao, Z Hu, R Mezzadra, L Hoeijmakers, A Fauster, S Du, Z Yang, ... Cancer cell 41 (10), 1817-1828. e9, 2023 | 8 | 2023 |
| A Traceless Selection: Counter-selection System That Allows Efficient Generation of Transposon and CRISPR-modified T-cell Products R Mezzadra, A Hollenstein, R Gomez-Eerland, TN Schumacher Molecular Therapy-Nucleic Acids 5, 2016 | 4 | 2016 |
| Molecular characterization of acquired resistance to KRAS G12C inhibition in gastrointestinal cancers S Misale, R Yaeger, R Mezzadra, J Sinopoli, Y Bian, M Marasco, ... | 1 | 2022 |
| Abstract B188: CMTM6, beyond a regulator of PD-L1 expression C Sun, R Mezzadra, R Gomez-Eerland, I Hofland, D Peters, A Broeks, ... Cancer Immunology Research 7 (2_Supplement), B188-B188, 2019 | | 2019 |
| Genetic manipulation and genetic-based dissection of tumor-specific immunity R Mezzadra cell 33 (2015), 2014 | | 2014 |
